Gilead eases HIV supply chain fears amid COVID-19 concern by Kyle Blankenship Tuesday, March 24, 2020 With COVID-19 hopeful remdesivir facing shortages, Gilead Sciences is trumpeting the strength of its HIV drug supply chain to end concerns.
AbbVie lands 3 brands in pharma's top February TV spenders by Beth Snyder Bulik Sunday, March 29, 2020 Pharma TV ad spending returned to typical levels in February after an exceptionally robust January start for the year.
Descovy not worth the price over Truvada generics: Study by Eric Sagonowsky Tuesday, March 10, 2020 Gilead's new HIV prevention drug may be an improvement over its predecessor, Truvada, but it's not worth the premium price, researchers say.
Gilead launches first DTC ads for Descovy for HIV prevention by Beth Snyder Bulik Monday, February 10, 2020 Gilead Sciences rolled its first Descovy-for-PrEP campaign on TV as its winds down advertising for its first-generation PrEP drug Truvada.
Gilead's Truvada-Descovy PrEP switch is off to a good start by Angus Liu Tuesday, December 3, 2019 At the current rate, Gilead could switch about 50% to 60% of PrEP users off Truvada by the time Teva launches its 2020 copycat, analysts predict.
Trump admin sues Gilead over PrEP-related HIV patent by Eric Sagonowsky Thursday, November 7, 2019 Gilead Sciences balked at licensing the U.S. government's HIV-prevention patent rights, and now the feds are striking back.
Gilead riding Biktarvy success as HIV portfolio shows weakness by Kyle Blankenship Wednesday, November 6, 2019 Amid Gilead Sciences' flagging sales, HIV med Biktarvy has been a rare shining light. New safety data over a competitor could help its case.
Gilead's ready to spend big on Descovy, filgotinib launches: CEO by Carly Helfand Thursday, October 24, 2019 If Gilead’s investors are worried the company’s new leadership team won’t pony up to support key launches, they don’t need to be, its CEO says.
Gilead called on to 'significantly cut' Descovy's price in PrEP by Kyle Blankenship Monday, October 7, 2019 Gilead Sciences scored a major win with a pre-exposure nod for next-gen HIV/AIDS med Descovy. Now a consumer group wants the price significantly cut.
Clock's ticking for Gilead to switch PrEP patients to Descovy by Angus Liu Friday, October 4, 2019 The lack of warnings for bone mineral density loss could be a key selling point for Gilead to drive switching from Truvada to Descovy, analysts say.
